Beral, V., Doll, R., Hermon, C., Peto, R., Reeves, G., Schouten, L. J., & van den Brandt, P. A. (2008 
Introduction
Use of oral contraceptives has long been known to reduce the incidence of ovarian cancer.
1,2 Because ovarian cancer is not common in young women and the incidence increases with age, the public-health eff ect of this reduction depends mainly on how much the reduced risk persists decades after oral contraceptive use ceases. To investigate the relation between use of oral contraceptives and the subsequent risk of ovarian cancer, data for individual women from 45 epidemiological studies of ovarian cancer have been brought together, checked, and analysed centrally.
Methods

Identifi cation of studies and collection of data
Epidemiological studies were eligible for this collaboration if they included at least 100 women with ovarian cancer (40 cases in cohort studies) and recorded information on each woman's reproductive history and use of oral contraceptives. Studies were identifi ed from review articles, from computer-aided literature reviews up to January 2006, using Medline, Embase, and PubMed, and from discussions with colleagues. Principal investigators from each eligible study were invited to participate. Of the 48 eligible studies identifi ed (including one multicentre international study 25, 31, 36 ) all but three [48] [49] [50] contributed to the collaboration. Individual data could not be retrieved by the investigators from two of these three studies 48, 49 and investigators for the third 50 could not be located. Cases were defi ned as women with malignant epithelial or non-epithelial ovarian cancer and controls were women without ovarian cancer who had not undergone bilateral oophorectomy. Data for individual women were sought from principal investigators of every study on socio-demographic factors, reproductive and menstrual history, use of hormonal contraceptives, use of hormonal therapies for the menopause, height, weight, family history of breast and ovarian cancer, and consumption of alcohol and tobacco. Cohort studies were incorporated using a nested case-control design, in which up to four controls were selected at random, matched for follow-up duration, age of the case at diagnosis, and, where appropriate, by broad geographical region. Data provided by investigators were checked and collated centrally so that analyses could be done using defi nitions as similar across studies as was possible. Apparent inconsistencies in the data were rectifi ed, where possible, by correspondence with the investigators. After the records had been checked and corrected, investigators were sent summary tables and listings of the variables to be used in analyses for fi nal confi rmation.
Information on the histological classifi cation of the ovarian cancers had been collected by principal investigators of all but 12 of the 45 participating studies.
1,5,6,10,12,15,16, 21, 22, 26, 30, 45 The classifi cation system adopted in each study was used centrally to categorise tumours as epithelial or non-epithelial and, among the epithelial tumours, to categorise them further as clear cell, endometrioid, mucinous, serous, mixed, or other, according to the 10th revision of the International Classifi cation of Diseases (ICD10). 51 Whenever possible epithelial tumours were further categorised as to whether they were borderline malignant or fully malignant.
51
Defi ning oral contraceptive use
Principal investigators of every participating study had collected information on whether individual women had ever used oral contraceptives, and most had also collected information on total duration of use, age at fi rst and last use, and calendar year of fi rst and last use. The cases had been diagnosed with ovarian cancer on average about 20 years after they had fi rst used oral contraceptives. Validation studies have shown that, although women were able to recall whether or not they took oral contraceptives in the past, their ability to recall reliably which preparations they used declined soon after use ceased. 52 There is, however, a strong relation between calendar year of use and the dose of oestrogen in the oral contraceptives typically used. 29, 53, 54 In the USA and UK, for example, the oral contraceptives prescribed before 1970 were typically high-dose preparations, often containing 100 μg or more of oestrogen; between 1970 and 1980 prescriptions were typically for medium-dose preparations containing about 50 μg of oestrogen; and by 1980 most prescriptions were for low-dose preparations, containing 30 μg or less of oestrogen. 53, 54 Calendar year of oral contraceptive use could therefore be taken, at least roughly, to be a proxy for oestrogen dose and women were classifi ed according to the mid-year of use (before 1970, 1970-79, and 1980 or after) to correspond to likely use of high-dose, medium-dose, and low-dose preparations. Sensitivity analyses were done, also classifying women by the calendar year of fi rst and last use. Although most studies did not distinguish between oral contraceptives containing oestrogen-progestagen combinations and preparations containing progestagens only, more than 95% of oral contraceptives used in these populations would have been of the combined type. 55 
Statistical analysis and presentation of results
The statistical methods were similar to those used when analysing the worldwide data for the eff ects of oral contraceptives on breast cancer. 55 Data from diff erent studies were combined by means of the Mantel-Haenszel stratifi cation technique, the stratum-specifi c quantities calculated being the standard "observed minus expected" (O-E) numbers of women with ovarian cancer, together with their variances and covariances. [55] [56] [57] Use of these simple stratifi ed O-E values has the advantage of avoiding assumptions about the precise forms of any relations in the data. The stratifi ed O-E values, together with their variances and covariances, yield both odds ratios (subsequently referred to as relative risks) and associated p values. When two groups only are compared, relative risk estimates are obtained from the O-E value and its variance (V) by the one-step method 56, 57 as are their standard errors (SE) and CIs. The actual formulae are: log relative risk=(O-E)/V; and its variance=1/V. When more than two groups are compared, variances are estimated by treating the relative risks as fl oating absolute risks (FARs). 58 This To ensure that women in one study were compared directly only with similar women in the same study, all analyses were routinely stratifi ed by study, by centre within study, by fi ne divisions of age (single years of age from 16 to 69, then 70-74, 75-79, 80-84, and 85-89), parity (0, 1, 2, 3, 4, 5, 6+; not known) and hysterectomy status (yes, no, unknown). These stratifi cation variables were selected because they are related both to the use of oral contraceptives and to the risk of developing ovarian cancer. The eff ect on the main fi ndings of 12 other potential confounding factors (ethnic group, education, age at fi rst birth, family history of breast cancer, age at menarche, menopausal status, use of hormone replacement therapy, height, weight, body-mass index, alcohol use, and smoking) was examined by comparing results before and after stratifi cation for each variable separately and all simultaneously.
When results in the fi gures are represented by squares and lines the position of the square indicates the value of the relative risk (its area is inversely proportional to the variance of the logarithm of the relative risk, thereby providing an indication of the amount of statistical 
Figure 1: Details of and results from studies contributing data for oral contraceptive use and ovarian cancer Dotted lines represent overall result for all women. *Stratifi ed by study, age, parity, and hysterectomy.
information available for that particular estimate) and the length of the line represents the CI. When appropriate, a trend in the relative risk of ovarian cancer with increasing duration of oral contraceptive use was calculated only among users (ie, relative risks for ever users were compared with each other). For these calculations and for the graphical presentation of such results, the duration of oral contra ceptive use associated with a particular category was taken to be the median duration within that category.
To estimate the absolute risk of ovarian cancer associated with 5, 10, and 15 years use of oral contraceptives, the relative risks obtained here were applied to published data for the age-specifi c incidence and mortality rates for ovarian cancer in high income countries. 59, 60 The age-specifi c rates were then used to estimate cumulative rates up to age 75. To illustrate the public-health eff ect of oral contraceptives on ovarian cancer, the numbers of cancers prevented in each of the fi ve decades, starting with the 1960s, were estimated by applying the relative risks found here and statistics on oral contraceptive use in diff erent generations of women to age-specifi c ovarian cancer incidence and mortality rates. In high-income countries the estimated proportions of ever-users of oral contraceptives in each successive 5-year birth cohort from 1916-20 to 1951-55 were: 5%, 15%, 29%, 40%, 51%, 65%, 76%, and 80%, respectively, with the average years of use among them being 3·6, 4·5, 5·1, 5·5, 5·8, 6·1, 6·3, and 6·3, respectively. These estimates were based on the pattern of oral contraceptive use recorded among controls in this collaboration and in a previous international collaboration; 55 for women born after 1955 use was assumed to be the same as for the 1951-55 birth cohort. In middle-income and low-income countries, oral contraceptive use was uncommon until recently.
61,62
Role of the funding source
The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the report. The writing committee had full access to all the data and had fi nal responsibility for the decision to submit for publication.
Results
Details of the 45 participating studies are shown in table 1. The studies are listed according to their design and, within each type of design, by the median year when the ovarian cancers were diagnosed in each study. Altogether the 45 studies were done in 21 countries, mostly in Europe or the USA, and they contributed a total of 23 257 women with ovarian cancer (cases) and 87 303 women without ovarian cancer (controls) to the analyses. The cancers were diagnosed in 1993, on average, and the mean age at diagnosis was 56 years; 7% were aged younger than 35 years, 11% were aged 35-44 years, 25% were aged 45-54 years, 30% were aged 55-64 years, and 27% were older.
Overall, 31% (7308) of the women with ovarian cancer and 37% (32 717) of the controls had used oral contraceptives, and the average duration of use was 4·4 and 5·0 years, respectively. Figure 1 shows the study-specifi c and combined relative risks of ovarian cancer in ever-users compared with never-users of oral contraceptives. (Studies with information content [var (O-E)] less than 20 are included in the "other" category for the relevant study design.) For each of the three types of study design there was a highly signifi cant reduction in the relative risk of ovarian cancer in ever users of oral contraceptives. Overall, for ever vs never users the overall relative risk is 0·73, 95% CI 0·70-0·76, p<0·0001.
The longer that women had used oral contraceptives, the lower their risk of ovarian cancer (table 2). The overall relative risk decreased by 20% (95% CI, 18-23%, p<0·0001) for each 5 years of use (ie, it was multiplied by a factor of 0·8). In women who had used oral contraceptives for about 15 years the risk of ovarian cancer was halved (fi gure 2). The eff ect of various potential confounding factors on the relation shown in fi gure 2 was examined by adjusting in turn for ethnic group, education, age at fi rst birth, family history of breast cancer, age at menarche, menopausal status, use of hormone replacement therapy, height, weight, body-mass index, alcohol use, and tobacco consumption and also by adjusting for all the factors simultaneously. All these additional adjustments altered the estimated 20% decrease in relative risk per 5 years use by less than 1%. The women with ovarian cancer had stopped use of oral contraceptives an average of 18·6 years previously, and table 3 shows results by time since ceasing use. The relative risks for ovarian cancer were lower the more recently women had used oral contraceptives. The average duration of use was, however, greater in recent users than in those who had stopped a long time previously (table 3) . When the relation with duration of use was examined within categories of recency of use, there was some wearing off of the eff ect of oral contraceptives the longer ago use had ceased: the proportional declines in relative risk per 5 years use of oral contraceptives were 29% for those whose use had ceased less than 10 years previously, 19% for use ceased 10-19 years previously, and 15% for use ceased 20-29 years previously (test for heterogeneity, p=0·004, fi gure 3). These fi ndings are unlikely to indicate misclassifi cation of use long ago, since women recall reliably whether or not they took oral contraceptives in the past (but cannot recall the type used). 52 Despite this attenuation in proportional (but not in absolute) risk reduction after stopping use, the risk of ovarian cancer was still signifi cantly reduced 30 or more years after use had ceased (table 3) . Once duration of use and time since last use of oral contraceptives were taken into account, no other index of the timing of use-eg, women's ages at fi rst and last use, and use before and after the birth of a child-had any material further eff ect on the relative risk of ovarian cancer. Table 4 shows results according to the women's ages at fi rst use of oral contraceptives. There was no signifi cant heterogeneity in the decline in relative risk with increasing duration of oral contraceptive use across women who started use at diff erent ages (test for heterogeneity, p=0·5). The distribution of women's ages at fi rst use was 16% for those younger than 20 years, 34% for 20-24 years, 21% for 25-29 years, 14% for 30-34 years, 8% for 35-39 years, and 7% for older ages. Women's ages at last use were closely correlated with their age at fi rst use, and the decline in ovarian cancer risk with increasing duration of use did not diff er signifi cantly by women's age at last use (3% were younger than 20 years at last use, 18% were 20-24, 24% were 25-29, 21% were 30-34, 15% were 35-39, 11% were 40-44, and 8% were older). The decline in ovarian cancer risk with increasing duration of use did not vary signifi cantly by whether women had begun using oral contraceptives before or after the birth of their fi rst child (decreases in relative risk per 5 years of use 26% vs 18%; test for heterogeneity, p=0·1).
As described in the methods section, the oestrogen dose in oral contraceptive preparations typically used in the 1960s was more than double that of preparations typically used in the 1980s. 29 contraceptive use in the 1960s and 13% had a mid-year of use in the 1980s or later (table 5) . Those with a mid-year of use in the 1960s had, as expected, ceased use much longer ago than those with a mid-year of use in the 1980s or later (25 years vs 5 years previously). For a given time since last use, however, calendar year of use had little eff ect on the relative risk of ovarian cancer (table 5) . Sensitivity analyses were done classifying women according to the calendar year of fi rst use and calendar year of last use but, again, no obvious diff erences in ovarian cancer risk were found. The magnitude of the decline in the relative risk of ovarian cancer with duration of use did not vary signifi cantly according to 13 of the 15 personal characteristics examined (fi gure 4). Signifi cant variation was seen only with age at diagnosis and menopausal status. However, the younger and pre-menopausal women had ceased use of oral contraceptives more recently than the older and postmenopausal women. When analyses were restricted to women whose use ceased 10-29 years previously (the only group with broadly similar recency of use and also with suffi cient information to compare younger versus older women and pre-menopausal versus post-menopausal women), there was no signifi cant heterogeneity by either age (p=0·1) or menopausal status (p=0·4). There was some variation in the magnitude of the decline in relative risk of ovarian cancer for each year of use of oral contraceptives across studies (χ²₂₇=49·1, p=0·006; fi gure 1) and by study design (χ²₂=10·4, p=0·006). This heterogeneity again refl ects the variation in age and thus time since last use of oral contraceptives: cases in the prospective compared with the case-control studies were older (mean ages of 64 vs 52 years at diagnosis) and had ceased use longer ago (means of 24 vs 15 years since last use).
Data for histological subtype was available for 17 099 women with ovarian cancer (74% of the total). Among these women the risk of ovarian cancer decreased by 21% for each 5 years of use of oral contraceptives (fi gure 5), similar to the 20% seen for all women (fi gure 1). The reductions in risk per 5 years of oral contraceptive use were broadly similar for epithelial and non-epithelial tumours. Among the epithelial tumours there was, however, heterogeneity across histological types (test for heterogeneity, p=0·0007), mainly because oral contraceptives seem to have little eff ect on mucinous tumours (12% of the total with histology). There was no signifi cant heterogeneity in the trends with duration of use between the non-mucinous epithelial tumours (p=0·5). The fi ndings were similar when the mucinous and serous tumours were subdivided into whether they were of only borderline malignancy or were fully malignant (fi gure 5). Figure 6 shows, for women in high income countries, the estimated cumulative incidence and mortality from ovarian cancer for never users of oral contraceptives and for those who used them for 5, 10, and 15 years, respectively, beginning at age 20 years. The percent decline in ovarian cancer rates for every 5 years of use was assumed to be 29% in current users and those who ceased use in the previous 10 years, 19% in those who ceased use 10-19 years previously, and 15% in those who ceased use 20 or more years previously. For women who never used oral contraceptives an estimated 1·2 in every 100 are diagnosed with ovarian cancer and 0·7 in every 100 die from the disease before the age of 75 years (in the absence of other causes of death). For 10 years use of oral contraceptives the estimated cumulative incidence was 0·8 per 100 and mortality was 0·5 per 100. As the reduction in risk is roughly proportional to duration of use, this means that for every 5000 woman-years of oral contraceptive use about two ovarian cancers and one death from the disease are prevented. (Ovarian cancers arising after age 75 years are not included in these or in subsequent calculations, nor are deaths from ovarian cancer after age 75 years that arose earlier.)
For women with background rates of ovarian cancer greater than the average, such as those with a family history of breast cancer or who are nulliparous, the reduction in absolute risk would be greater still. Conversely, for women with lower than average background rates the reduction in absolute risk would be less. For example, ovarian cancer rates in many middle-income and low-income countries are about half those in high income countries, 59 ,60 and so about two ovarian cancers and one death from the disease would be prevented for every 10 000 woman-years of oral contraceptive use.
Discussion
This worldwide collaboration has brought together and re-analysed data for over 23 000 women with ovarian cancer and 87 000 women without ovarian cancer from 21 countries. The results confi rm that women who use oral contraceptives are at a reduced risk of ovarian cancer and show that substantial protection continues for decades. The reduction in risk is greater the longer that women used oral contraceptives and, although the relative (but not the absolute) risks are somewhat attenuated over time, there is still a signifi cant reduction in risk more than 30 years after use has ceased. The relative decline in ovarian cancer risk with increasing duration of use does not vary substantially by women's ethnicity, education, age at menarche, parity, family history of breast cancer, use of hormone replacement therapy, body-mass index, height, or their consumption of alcohol and tobacco. The incidence of mucinous tumours (12% of the total) was little aff ected by oral contraceptives, but otherwise the proportional risk reduction did not vary much between diff erent histological types.
This collaboration includes individual data from 45 epidemiological studies, most of the eligible studies worldwide that have collected information on oral contraceptive use and ovarian cancer. Despite extensive eff orts to identify studies with unpublished results, we cannot guarantee that none has been overlooked or that information from continuing prospective studies is up to date, since such studies are accumulating data beyond the time when they contributed to this collaboration. Three published studies [48] [49] [50] could not contribute their data, and only some of the EPIC study centres 25, 30, 36 have done so. Nevertheless, these studies would have increased the number of cases by only about another 3%, and the published results from the studies not included [48] [49] [50] do not diff er from those reported. Thus, failure to include all the available data has not materially altered the overall fi ndings.
Substantial reductions in the oestrogen content of oral contraceptives have occurred over the 50 or so years that oral contraceptives have been in use. The ovarian cancers in this study were diagnosed, on average, almost 20 years after the women had last used oral contraceptives and, because the specifi c oral contraceptive preparations used are unreliably reported many years after use ceases, 52 calendar year is used here as an indicator of the average oestrogen dose of the preparations. Typical oestrogen doses in the 1960s were more than double the typical doses in the 1980s and later, 29, 53, 54 but for a given pattern of usage there was no apparent variation in the relative risk of ovarian cancer between women whose oral contraceptive use was during the 1960s, 1970s, and 1980s (table 5), sug gesting no appreciable diff erential eff ect of prep arations typically used over the decades.
One of the main eff ects of oral contraceptives is to suppress ovarian activity, so some protection against neoplastic change is plausible. This makes it reasonable to infer that the associations seen here are chiefl y causal-ie, that previous oral contraceptive use decreases the age-specifi c incidence of ovarian cancer in otherwise similar women. The exact mechanism by which oral contraceptives cause such a profound and long-lasting protection against ovarian cancer is, nevertheless, not well understood.
Oral contraceptives were fi rst licensed almost 50 years ago. In the 1960s and 1970s most women who had used oral contraceptives were younger than 50 and so relatively few ovarian cancers would have been prevented (table 6) . In subsequent decades the estimated proportion of cancers prevented increased, in part due to the increasing number of ever-users and in part due to the increasing age of past users, such that in the 2000s an estimated 13% of ovarian cancers before age 75 years were being prevented in women in high-income countries. In middleincome and low-income countries oral contra ceptives have probably had little eff ect so far on ovarian cancer incidence, since use was uncommon until the 1980s. 61, 62 To illustrate the public-health implications of relative risks such as those reported here and the pattern of oral contraceptive use around the world, these results suggest that of the order of 200 000 incident cases and 100 000 deaths from ovarian cancer have already been prevented over the last 50 years. The number of cancers prevented each year is likely to increase substantially in the future, with the further ageing of past users of oral contraceptives and the increasing numbers of new users, especially in middle-income and low-income countries. In 2002 an estimated 80 million of a total of 120 million oral contraceptives users worldwide were in middle-income and low-income countries. 61 With this number of oral contraceptive users and current ovarian cancer incidence rates, the number of ovarian cancers prevented would rise over the next few decades to about 30 000 every year. However, the number prevented is likely to be still greater since the prevalence of oral contraceptive use in middle-income and low-income countries is predicted to increase. 62 
